Literature DB >> 843425

The pharmacokinetics of ciclazindol (Wy 23409) in human volunteers.

A J Swaisland, R A Franklin, P J Southgate, A J Coleman.   

Abstract

1. The pharmacokinetics and metabolism of ciclazindol, a potential anti-depressant drug, have been studied after oral administration of the compound to male and female volunteers. 2. The mean +/- S.E. mean maximum plasma concentration of the unchanged drug was 422 +/- 31 ng/ml. This level was seen between 2 and 4 h after dosing. 3. Elimination of the ciclazindol from plasma was apparently monexponential with a half-life of approximately 32 h. A large proportion of the drug-related substances in the plasma was unchanged drug. 4. Excretion of radioactivity took place predominantly via the renal route, less than 15% of the dose being recovered in the faeces. The urinary elimination process was apparently monoexponential with a half-life of 28 h. 5. Daily dosing with ciclazindol for 3 weeks did not appear to induce the enzymes of its own metabolism.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 843425      PMCID: PMC1428987          DOI: 10.1111/j.1365-2125.1977.tb00668.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  Pharmacokinetic studies on WY 23409 HCl.

Authors:  A J Swaisland; R A Franklin; R J Southgate
Journal:  Br J Clin Pharmacol       Date:  1975-10       Impact factor: 4.335

2.  Clinical implications of enzyme induction.

Authors:  A Breckenridge; M Orme
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

3.  Drug urinary excretion data--some aspects concerning the interpretation.

Authors:  B K Martin
Journal:  Br J Pharmacol Chemother       Date:  1967-02

4.  Folate deficiency after anticonvulsant drugs: an effect of hepatic enzyme induction?

Authors:  J D Maxwell; J Hunter; D A Stewart; S Ardeman; R Williams
Journal:  Br Med J       Date:  1972-01-29

5.  The action of indoramin and other compounds on the uptake of neurotransmitters into rat cortical slices.

Authors:  R F Sugden
Journal:  Br J Pharmacol       Date:  1974-07       Impact factor: 8.739

  5 in total
  4 in total

1.  The biotransformation of ciclazindol in man.

Authors:  A J Swaisland; R A Franklin; A C White
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

2.  Comparison of the effects of chronic administration of ciclazindol and desipramine on pupillary responses to tyramine, methoxamine and pilocarpine in healthy volunteers.

Authors:  F A Kerr; E Szabadi
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

3.  Computer assisted shared care in hypertension.

Authors:  J C Petrie; O J Robb; J Webster; A K Scott; T A Jeffers; M D Park
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-29

4.  Ciclazindol: an oral agent with weight reducing properties and hypoglycaemic activity.

Authors:  M E Lean; L J Borthwick
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.